Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
93.8M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
32.7M
-
Shares change
-
+2.19M
-
Total reported value, excl. options
-
$617M
-
Value change
-
+$43.3M
-
Number of buys
-
59
-
Number of sells
-
-19
-
Price
-
$18.85
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q2 2021
89 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q2 2021.
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.7M shares
of 93.8M outstanding shares and own 34.91% of the company stock.
Largest 10 shareholders include FMR LLC (5.12M shares), PERCEPTIVE ADVISORS LLC (3.96M shares), ORBIMED ADVISORS LLC (3M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (2.71M shares), BlackRock Inc. (2.59M shares), Vivo Capital, LLC (1.75M shares), Bain Capital Life Sciences Investors, LLC (1.68M shares), VANGUARD GROUP INC (1.5M shares), 5AM Venture Management, LLC (1.36M shares), and BAKER BROS. ADVISORS LP (921K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.